Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 53 (3), 321-9

Pharmacological Actions of SM-9018, a New Neuroleptic Drug With Both Potent 5-hydroxytryptamine2 and dopamine2 Antagonistic Actions

Affiliations

Pharmacological Actions of SM-9018, a New Neuroleptic Drug With Both Potent 5-hydroxytryptamine2 and dopamine2 Antagonistic Actions

A Hirose et al. Jpn J Pharmacol.

Abstract

Pharmacological studies were undertaken to clarify the profile of cis-2-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl) butyl) hexahydro-1H-isoindole-1,3-(2H)-dione hydrochloride (SM-9018), a new neuroleptic drug. SM-9018 had very high binding affinities for both 5-hydroxytryptamine2 (5-HT2) and dopamine2 (D2) receptors, unlike many other neuroleptics. SM-9018 also strongly inhibited 5-HT2 receptor-mediated behavior such as tryptamine-induced clonic seizure and D2 receptor-mediated behavior such as methamphetamine-induced hyperactivity, apomorphine-induced stereotypy and climbing behavior. SM-9018 possessed only a weak cataleptogenic activity, which may be clinically related to extrapyramidal side effects, despite its potent D2 antagonistic activity. Moreover, SM-9018 induced weak central depressant effects such as inhibition of spontaneous locomotor activity and motor coordination, as compared with classical neuroleptics (haloperidol and chlorpromazine). These results suggest that SM-9018 is a new neuroleptic drug with both potent 5-HT2 and D2 antagonistic activities and with low cataleptogenic and central depressant activities.

Similar articles

See all similar articles

Cited by 8 PubMed Central articles

See all "Cited by" articles

MeSH terms

Feedback